292 related articles for article (PubMed ID: 21350000)
1. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
Sano D; Matsumoto F; Valdecanas DR; Zhao M; Molkentine DP; Takahashi Y; Hanna EY; Papadimitrakopoulou V; Heymach J; Milas L; Myers JN
Clin Cancer Res; 2011 Apr; 17(7):1815-27. PubMed ID: 21350000
[TBL] [Abstract][Full Text] [Related]
2. Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.
Sano D; Fooshee DR; Zhao M; Andrews GA; Frederick MJ; Galer C; Milas ZL; Morrow PK; Myers JN
Head Neck; 2011 Mar; 33(3):349-58. PubMed ID: 20629091
[TBL] [Abstract][Full Text] [Related]
3. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Gustafson DL; Frederick B; Merz AL; Raben D
Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma.
Klein JD; Christopoulos A; Ahn SM; Gooding WE; Grandis JR; Kim S
Head Neck; 2012 Sep; 34(9):1269-76. PubMed ID: 22307735
[TBL] [Abstract][Full Text] [Related]
5. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.
Macha MA; Rachagani S; Qazi AK; Jahan R; Gupta S; Patel A; Seshacharyulu P; Lin C; Li S; Wang S; Verma V; Kishida S; Kishida M; Nakamura N; Kibe T; Lydiatt WM; Smith RB; Ganti AK; Jones DT; Batra SK; Jain M
Oncotarget; 2017 Mar; 8(13):20961-20973. PubMed ID: 28423495
[TBL] [Abstract][Full Text] [Related]
6. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
7. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
Choi S; Sano D; Cheung M; Zhao M; Jasser SA; Ryan AJ; Mao L; Chen WT; El-Naggar AK; Myers JN
Clin Cancer Res; 2008 Aug; 14(16):5081-9. PubMed ID: 18698025
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
Wachsberger PR; Lawrence YR; Liu Y; Daroczi B; Xu X; Dicker AP
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):483-91. PubMed ID: 21095630
[TBL] [Abstract][Full Text] [Related]
9. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.
Ekshyyan O; Rong Y; Rong X; Pattani KM; Abreo F; Caldito G; Chang JK; Ampil F; Glass J; Nathan CO
Mol Cancer Ther; 2009 Aug; 8(8):2255-65. PubMed ID: 19625495
[TBL] [Abstract][Full Text] [Related]
10. Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment.
Chu PL; Shihabuddeen WA; Low KP; Poon DJJ; Ramaswamy B; Liang ZG; Nei WL; Chua KLM; Thong PSP; Soo KC; Yeo ELL; Chua MLK
Photodiagnosis Photodyn Ther; 2019 Sep; 27():367-374. PubMed ID: 31299389
[TBL] [Abstract][Full Text] [Related]
11. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
[TBL] [Abstract][Full Text] [Related]
12. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model.
Lee TK; Poon RT; Wo JY; Ma S; Guan XY; Myers JN; Altevogt P; Yuen AP
Cancer Res; 2007 Sep; 67(18):8800-9. PubMed ID: 17875721
[TBL] [Abstract][Full Text] [Related]
13. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
[TBL] [Abstract][Full Text] [Related]
14. Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma.
Kitamura S; Maeda T; Yanagi T
Biochem Biophys Res Commun; 2020 Oct; 531(3):396-401. PubMed ID: 32800552
[TBL] [Abstract][Full Text] [Related]
15. AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo.
Torres MA; Raju U; Molkentine D; Riesterer O; Milas L; Ang KK
Invest New Drugs; 2011 Aug; 29(4):554-61. PubMed ID: 20119866
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.
Papadimitrakopoulou VA; Frank SJ; Cohen EW; Hirsch FR; Myers JN; Heymach JV; Lin H; Tran HT; Chen CR; Jimeno A; Nedzi L; Vasselli JR; Lowe ES; Raben D
Head Neck; 2016 Mar; 38(3):439-47. PubMed ID: 25352401
[TBL] [Abstract][Full Text] [Related]
17. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
Huang SM; Li J; Armstrong EA; Harari PM
Cancer Res; 2002 Aug; 62(15):4300-6. PubMed ID: 12154033
[TBL] [Abstract][Full Text] [Related]
18. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
Nozawa H; Tadakuma T; Ono T; Sato M; Hiroi S; Masumoto K; Sato Y
Cancer Sci; 2006 Oct; 97(10):1115-24. PubMed ID: 16984384
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma.
Sano D; Kawakami M; Fujita K; Kimura M; Yamashita Y; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
Oncol Rep; 2007 Feb; 17(2):289-95. PubMed ID: 17203163
[TBL] [Abstract][Full Text] [Related]
20. Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation.
McNally LR; Rosenthal EL; Zhang W; Buchsbaum DJ
Cancer Gene Ther; 2009 Mar; 16(3):246-55. PubMed ID: 18846112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
